• Revenue for Q1 decreased 9% to $0.51m
• Cash on hand decreased 27% to $0.71m
• Operating cash outflow increased to $0.89m

Uscom Ltd (ASX: UCM) has released its 4C cash report for the quarter ending 30 September 2025. The key results disclosed include:Revenue: Q1 receipts from customers decreased 9% to $0.51m from $0.55m in the prior period and decreased 15% from $0.59m in the prior corresponding period.Cash Flow: Uscom reported cash on hand of $0.71m, a decrease of 27% from the prior period of $0.97m. Operating cash outflow was $0.89m, an increase from an outflow of $0.72m in the prior period.Expenditure: Product manufacturing and operating costs increased 159% to $0.23m from $0.09m in the prior corresponding period, while admin and corporate expenses decreased 72% from the prior corresponding period to $0.21m.Commentary from Executive Chairman Professor Rob Phillips noted that Q1 remained difficult in all regions except Southeast Asia, which continues to achieve forecasts. He cited the shifting US Tariff wars, global uncertainty, and the impact on healthcare funding in Europe due to the Russian war as factors impacting performance. However, Professor Phillips expressed confidence in the long-term outlook for Uscom's cardiovascular and pulmonary technologies, which address conditions responsible for over 75% of human mortality.

Uscom management remains focused on complying with changing global regulatory demands and complex regional administrative requirements. Longer term, the company is confident that personal healthcare, a market in the order of $100 billion USD, will remain a significant and critical social focus, and that Uscom's innovative technologies will have enduring healthcare value by improving quality and duration of life.